乌帕替尼缓释片治疗难治性中重度特应性皮炎72周之临床观察一例

A Case of Refractory Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib Sustained-Release Tablets for 72 Weeks: A Clinical Observation

摘要: 特应性皮炎，是一种慢性复发性、瘙痒性、炎症性皮肤病。该文报道四川首例使用乌帕替尼缓释片患者，该患者为59岁男性，因全身反复泛发对称性红色斑丘疹、结节伴瘙痒10⁺年就诊。近10年经过常规治疗、选择性JAK抑制剂、生物制剂等治疗后效果欠佳，症状反复发作。患者使用乌帕替尼缓释片治疗1天后全身瘙痒症状缓解，7天后瘙痒症状完全消失，皮损面积减少、严重程度降低，生活质量提高。随访72周，患者全身皮损消退，未见明显新发皮损。该例提示使用乌帕替尼缓释片作为选择性JAK1抑制剂治疗常规治疗无效或效果不佳的难治性、中重度AD患者是可以迅速且持久获益的。

Abstract: Atopic dermatitis is a chronic recurrent, pruritus, inflammatory skin disease. This article reports on the first patient in Sichuan to use Upadacitinib sustained-release tablets. The patient is a 59-year-old male with a history of recurrent symmetric red papules and nodules accompanied by itching all over the body for over 10 years. Over the past decade, various treatments such as conventional therapy, selective JAK inhibitors, and biologics were administered with suboptimal efficacy, and symptoms recurred. The patient experienced relief from itching throughout the body and a reduction in the area and severity of skin lesions within one day of initiating Upadacitinib treatment. Complete resolution of itching was observed after 7 days, leading to an improvement in the quality of life. During the 72-week follow-up, the patient’s systemic skin lesions subsided and no significant new skin lesions were observed. This case suggests that the use of Upadacitinib sustained-release tablets as a selective JAK1 inhibitor in the treatment of refractory, moderate-to-severe AD patients who have failed or failed to respond to conventional therapy may be of rapid and lasting benefit.